. . . "[36EE08675776]" . "Zmekov\u00E1, V\u00E1clava" . "Klamov\u00E1, Hana" . . "BCR-ABL mutations in chronic myeloid leukemia : not only detection" . "RIV/00023736:_____/08:00007641" . . . "BCR-ABL mutations in chronic myeloid leukemia : not only detection"@en . "Pro \u010Dasnou detekci rezistence na l\u00E9\u010Dbu inhibitory tyrozinov\u00FDch kin\u00E1z je d\u016Fle\u017Eit\u00E9 sledovat p\u0159\u00EDtomnost, typ a kinetiku BCR-ABL mutac\u00ED spolu s kinetikou celkov\u00E9ho transkriptu BCR-ABL, co\u017E p\u0159in\u00E1\u0161\u00ED v\u00EDce kompexn\u00ED pohled na pr\u016Fb\u011Bh onemocn\u011Bn\u00ED. Zjistili jsme, \u017Ee prvn\u00ED indikac\u00ED pro anal\u00FDzu mutac\u00ED je ji\u017E zastaven\u00ED klesaj\u00EDc\u00EDho trendu BCR-ABL na hladin\u00E1ch vy\u0161\u0161\u00EDch 0.1%. Pacienti odpov\u00EDdaj\u00EDc\u00ED suboptim\u00E1ln\u011B by m\u011Bli b\u00FDt testov\u00E1ni na p\u0159\u00EDtomnost mutac\u00ED ka\u017Ed\u00E9 t\u0159i m\u011Bs\u00EDce obdobn\u011B, jak je doporu\u010Dov\u00E1no pro kvantifikaci BCR-ABL."@cs . "3"^^ . . . . . "1042-8194" . "Zemanov\u00E1, Z." . . "Leukemia and Lymphoma" . "49" . "P(NR8758)" . "CML; BCR-ABL; mutation; resistance"@en . "Machov\u00E1-Pol\u00E1kov\u00E1, Kate\u0159ina" . "357700" . "000258906500027" . . . . . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "For early detection of resistance relapse it is important to follow-up the presence, type and kinetics of BCR-ABL mutation together with the kinetics of BCR-ABL transcript level, which provide more complex data on disease status. We found that the first indicator for mutation analysis in tyrosine kinase inhibitor responders is already the cessation of BCR-ABL decreasing trend, mainly when the BCR-ABL level stops above 0.1%. In patients with suboptimal response, the mutation analysis should be performed three-monthly as recommended for BCR-ABL quantifications according to current guidelines." . . "Moravcov\u00E1, Jana" . "6"^^ . "RIV/00023736:_____/08:00007641!RIV09-MZ0-00023736" . . "5"^^ . "Rulcov\u00E1, Jana" . . . "For early detection of resistance relapse it is important to follow-up the presence, type and kinetics of BCR-ABL mutation together with the kinetics of BCR-ABL transcript level, which provide more complex data on disease status. We found that the first indicator for mutation analysis in tyrosine kinase inhibitor responders is already the cessation of BCR-ABL decreasing trend, mainly when the BCR-ABL level stops above 0.1%. In patients with suboptimal response, the mutation analysis should be performed three-monthly as recommended for BCR-ABL quantifications according to current guidelines."@en . . "BCR-ABL mutations in chronic myeloid leukemia : not only detection"@en . "BCR-ABL mutace u chronick\u00E9 myeloidn\u00ED leuk\u00E9mie : nejen detekce"@cs . "8" . "BCR-ABL mutace u chronick\u00E9 myeloidn\u00ED leuk\u00E9mie : nejen detekce"@cs . "BCR-ABL mutations in chronic myeloid leukemia : not only detection" .